Recent studies have reported myricetin’s mechanisms of action in diabetes, such as inhibiting DPP4 [210], being an inactivator of GLP-1, or serving as a GLP-1 receptor agonist [211]. This evidence concerns the gene GLP1R and diabetes mellitus.